SUSAN G. KOMEN recently announced $26 million in funding for new research projects that focus on metastatic breast cancer, new treatments, and disparities in breast cancer outcomes. This year’s grant slate focuses on key areas that will help the organization achieve its bold goal to reduce the current number of breast cancer deaths in the United States by 50% by 2026.
Among the 60 grants Komen awarded, 38 are focused on improving scientific understanding and the treatment of metastatic breast cancer. Grants were also given to researchers who are developing new therapies, investigating drug resistance, and addressing health disparities in breast cancer outcomes among specific communities.
Closer Look at Grants
Komen’s 2019 portfolio includes 60 grants totaling $25,689,384. (The numbers add up to more than 60 because individual studies may be classed in more than one category.)
The following grants are included in these totals:
- 38 grants, totaling $17,504,384, focused on learning why metastasis occurs as well as how to prevent and treat patients with metastatic breast cancer
- 39 grants, totaling $15,579,815, for catalyzing the development of new therapies for all stages of breast cancer
- 16 grants looking into novel treatments for triple negative breast cancer
- 14 grants, totaling $6,298,750, studying drug resistance
- 9 grants focused on disparities in breast cancer outcomes
- 5 grants that apply big data technology to breast cancer research. ■
